Literature DB >> 6218778

Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

L C Preheim, R G Penn, C C Sanders, R V Goering, D K Giger.   

Abstract

In four patients with Pseudomonas aeruginosa infections, the infecting strain developed resistance to moxalactam during therapy with this drug. In addition, P. aeruginosa isolates from two of these four patients showed increased resistance to aminoglycosides. Isolates from a third patient acquired cross-resistance to other antipseudomonal beta-lactams. In three of the cases, disk susceptibility tests failed to detect the resistance that was demonstrated in broth dilution assays. Isolate identities were confirmed by serotyping. No new plasmids were found by agarose gel electrophoresis. The mechanisms for this resistance did not involve enzymatic antibiotic degradation. These findings suggest that currently available expanded-spectrum cephalosporin derivatives should probably not be used alone for most serious infections due to P. aeruginosa. They also suggest that strains with multiple antibiotic resistance may become more prevalent in hospitals if these drugs are used extensively.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6218778      PMCID: PMC185717          DOI: 10.1128/AAC.22.6.1037

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

3.  Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

4.  Simple agarose gel electrophoretic method for the identification and characterization of plasmid deoxyribonucleic acid.

Authors:  J A Meyers; D Sanchez; L P Elwell; S Falkow
Journal:  J Bacteriol       Date:  1976-09       Impact factor: 3.490

5.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

6.  Therapy of obstetrical infections with moxalactam.

Authors:  R S Gibbs; J D Blanco; Y S Castaneda; P J St Clair
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

7.  Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.

Authors:  L G Reimer; S Mirrett; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.

Authors:  G M Trager; A P Panwalker; J B Malow; P E Porembski; C A Ramirez; F A Zar
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

9.  Clinical evaluation of moxalactam.

Authors:  W K Livingston; A M Elliott; W E Dismukes; C K Avent; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

10.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

View more
  43 in total

1.  In vitro antibacterial activity of KP-736, a new cephem antibiotic.

Authors:  T Maejima; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

2.  Mutation of Salmonella paratyphi A conferring cross-resistance to several groups of antibiotics by decreased permeability and loss of invasiveness.

Authors:  L Gutmann; D Billot-Klein; R Williamson; F W Goldstein; J Mounier; J F Acar; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

3.  AmpC and OprD are not involved in the mechanism of imipenem hypersusceptibility among Pseudomonas aeruginosa isolates overexpressing the mexCD-oprJ efflux pump.

Authors:  Daniel J Wolter; Nancy D Hanson; Philip D Lister
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Model system to evaluate the effect of ampD mutations on AmpC-mediated beta-lactam resistance.

Authors:  Amber J Schmidtke; Nancy D Hanson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa.

Authors:  M L Gates; C C Sanders; R V Goering; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

6.  Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa.

Authors:  F A Manian; R H Alford
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

7.  In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa.

Authors:  H Giamarellou; N P Zissis; G Tagari; J Bouzos
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

8.  In vitro comparison of Pseudomonas aeruginosa isolates with various susceptibilities to aminoglycosides and ten beta-lactam antibiotics.

Authors:  D H Wu; A L Baltch; R P Smith
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

9.  Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactam-resistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production.

Authors:  A S Bayer; P Lindsay; J Yih; L Hirano; D Lee; I K Blomquist
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

10.  In vitro and in vivo antibacterial activities of BO-1341, a new antipseudomonal cephalosporin.

Authors:  S Nakagawa; M Sanada; K Matsuda; T Hashizume; Y Asahi; R Ushijima; N Ohtake; N Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.